Mannitol

證據等級: L5

預測適應症: 10 個

Mannitol: From Osmotic Diuretic Therapy to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Mannitol’s registered original indication is not documented in the available regulatory data (a flagged data gap); it is generically known as an osmotic diuretic. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this is currently supported by 0 clinical trials and only 1 loosely related publication, which does not itself study mannitol as a treatment for this condition.

Quick Overview

Item	Content
Original Indication	Not documented in the evidence pack (registration/indication data gap). Mannitol is generically known as an osmotic diuretic (e.g., cerebral oedema, raised intracranial/intraocular pressure, forced diuresis)
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)
TxGNN Prediction Score	99.97%
Evidence Level	L5
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for mannitol is currently unavailable (data gap DG002). Based on known general pharmacology, mannitol is a sugar-alcohol osmotic agent that expands plasma volume and promotes water/solute diuresis; it is not part of a fixed combination product in this evidence pack, and its efficacy in a specific original indication cannot be confirmed here because no original_indications or approved indication text was returned.

NSIAD is a rare genetic disorder (typically caused by activating mutations in the vasopressin V2 receptor) that produces hyponatremia through inappropriate free-water retention, independent of ADH levels. There is no established mechanistic rationale linking osmotic diuresis with mannitol to correction of V2-receptor-driven water retention, and standard management of hyponatremic disorders instead relies on fluid restriction, urea, or vaptans. The single supporting publication (PMID 26706473) is a general review on pitfalls in evaluating hyponatremia and does not investigate mannitol as a therapeutic agent for NSIAD — it appears to have been retrieved on the basis of shared terminology (“hyponatremia”) rather than a demonstrated drug–disease relationship.

Given this, the TxGNN score for this candidate should be interpreted as a knowledge-graph association rather than mechanistically or clinically validated evidence. Reviewers should also note that other high-scoring predictions in this same evidence pack for mannitol (e.g., malignant hyperthermia susceptibility, acute pulmonary heart disease) show a recurring pattern of likely knowledge-graph confounding — such as co-formulation overlap with dantrolene, or disease-ontology overlap between “acute pulmonary heart disease” and ARDS — and in at least one case (nephrogenic diabetes insipidus) the literature suggests mannitol may worsen rather than treat the condition. This overall pattern warrants added scrutiny for any mannitol repurposing signal derived from this dataset.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26706473	2016	Review	European Journal of Internal Medicine	Describes common pitfalls in diagnosing and managing hyponatremia; discusses risks of both under- and over-treatment, but does not evaluate mannitol as a treatment for NSIAD specifically

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: A blocking data gap (DG001) has been identified — TFDA/SAHPRA-equivalent package insert warnings and contraindications have not yet been retrieved, and this must be resolved before any safety evaluation (Stage S1) can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale:

The predicted indication (NSIAD) has no clinical trial support and only one indirectly related publication that does not study mannitol itself; combined with the absence of mechanism-of-action data and the drug’s “Not marketed” status in South Africa (0 SAHPRA registrations), the evidence level is L5 (model prediction only).
Similar high-scoring predictions elsewhere in this evidence pack for mannitol appear to reflect knowledge-graph confounding (co-formulation and disease-ontology overlaps) rather than genuine pharmacological signals, reinforcing a cautious posture toward this candidate.

To proceed, the following is needed:

Resolve blocking data gap DG001: retrieve TFDA/SAHPRA package insert warnings, contraindications, and drug interaction data
Resolve data gap DG002: obtain confirmed mechanism of action data from DrugBank
Obtain confirmed original indication/registration data for mannitol (currently absent from the evidence pack)
Identify or commission dedicated pharmacological/mechanistic studies directly evaluating mannitol in NSIAD, rather than relying on general hyponatremia literature
Re-review the TxGNN knowledge-graph edges for this candidate to rule out confounding from co-administered/co-formulated agents before any further advancement
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.